Recent studies have shown that CRC patients with RAS mutations are resistant to biologics, such as monoclonal antibodies to epidermal growth factor receptor (EGFR) or vascular endothelial growth factor, when used in combination with chemotherapy.22 Here, EGFR is linked to colorectal carcinoma.